This 2014 study investigates the synergistic effects of the soybean-derived peptide lunasin combined with cytokines IL-2 and IL-12 on natural killer (NK) cells in the context of lymphoma immunotherapy. Lunasin enhances NK cell activation, increasing the expression of IFNγ and granzyme B, leading to improved cytotoxicity against lymphoma cells. Notably,
This review article explores the potential of nutraceutical proteins and peptides in cancer prevention and therapy. It examines biologically active compounds such as plant protease inhibitors, lactoferrin, lactoferricin, shark cartilage, plant lectins, and lunasin for their ability to modulate cancer cell behavior. Key mechanisms include the induction of apoptosis through
This 2005 review highlights lunasin, a 43-amino-acid peptide derived from soy, as a promising agent in cancer prevention. Lunasin demonstrates efficacy against chemical carcinogens and oncogenes in mammalian cells and a skin cancer mouse model. It internalizes into mammalian cells within minutes and localizes in the nucleus after 18 hours,
This 2014 study investigates the differential sensitivity of non-small cell lung cancer (NSCLC) cell lines to lunasin, a soy-derived peptide with anticancer properties. The research compares lunasin-sensitive H661 cells to resistant H1299 cells, revealing that lunasin internalization is higher in H661 cells. Lunasin interacts with integrins containing αv, α5, β1,
This study examines the role of the Bowman-Birk protease inhibitor (BBI) in enhancing the oral bioavailability and cancer-preventive activity of lunasin, a soy-derived peptide known for its epigenetic modulation properties. Lunasin binds to deacetylated histones and inhibits histone acetylation, thereby regulating gene expression involved in tumorigenesis. However, its effectiveness is
